Clinical

Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP, open a discussion surrounding payer considerations relating to the treatment of major depressive disorder (MDD).

Emerging therapies for psoriasis and psoriatic arthritis (PsA) include treatments that target interleukin (IL)-23 and IL-17, which could lead to the approval of new IL-23 and IL-17 inhibitors, as well as expanding the use of currently approved options.

Having a plan in place to educate providers and the pharmacy team has contributed to the success that Rocky Mountain Cancer Centers (RMCC) has had with rapidly implementing biosimilars, said Timothy Murphy, MD, medical oncologist/hematologist with RMCC.

Dr Siefker-Radtke explores unmet needs in the treatment of patients with urothelial cancer and how novel immunotherapies can address some of the challenges with traditional chemotherapy.

The findings follow recent data suggesting that esophageal dysmotility may be associated with eosinophilic esophagitis (EoE), which often presents with dysphagia.

A recently published report describes the diagnosis and treatment of a case of iron-deficiency anemia–associated thrombocytopenia secondary to recurrent nosebleeds.

Immune checkpoint inhibitors, either alone or in combination with chemotherapy, were associated with better outcomes in non–oncogene-addicted non–small cell lung cancer (NSCLC).

The FDA’s approval of teclistamab for relapsed/refractory (R/R) multiple myeloma makes it the first bispecific T-cell engager antibody to enter the treatment landscape.

The study sought to examine the safety and tolerability of gefapixant in Japanese patients with refractory or unexplained chronic cough.

A systematic review found that changes in neural mechanisms as a result of ketamine treatment could play a role in treatment outcomes of ketamine-assisted psychotherapy.

These new study data are based on 20 years of follow-up in 92 Chinese children with lupus nephritis.

Key considerations for appropriate MDS treatment selection are discussed by expert panelists.

Salman Fazal, MD, shares opinions regarding the role of hypomethylating agents (HMAs) in treatment for patients with MDS.

Highlighting their ability to quickly destroy malignant cells without antigen specificity, natural killer (NK) cells have been identified as an opportunity for use, particularly in cases where T cells are not effective.

According to the study authors, acute decompensated pulmonary hypertension (PH) is often accompanied by systemic congestion and right ventricular flow output, and because PH can be accompanied by acute kidney injury, renal replacement therapy (RRT) may be necessary.

The risks of 4 types of skin cancers were investigated among patients who have neurofibromatosis type 1, a multisystem autosomal dominant genetic syndrome characterized by loss of neurofibromin.

Repetitive transcranial magnetic stimulation offers an alternative solution that may be effective for treating depression in patients with adverse childhood experiences.

The index for eosinophilic esophagitis (EoE) was crafted based on a literature review by a multidisciplinary team of experts.

Data suggest that the technology may be an option for patients who are ineligible for autologous stem cell transplantation (ASCT) based on certain patient characteristics, prior treatments, stem cell availability, or tumor chemosensitivity.

Arlene Siefker-Radtke, MD, opens a discussion recapping the ESMO 2022 conference surrounding advanced and metastatic urothelial cancer.

Dr Millie Das, MD discusses updates from the 2022 World Conference on Lung Cancer regarding non-small cell lung cancer (NSCLC).

Although exercise during cancer treatment is encouraged, multiple myeloma can present special challenges, since there is an increased risk of bone fractures, pain, and other deformities.

Syma Iqbal, MD, shares final insights into the ESCC and GI cancer treatment landscape, emphasizing the utilization of key diagnostic tools and innovative treatment strategies.

Although group 1 pulmonary arterial hypertension (PAH) with comorbid syncope has been linked to a poor prognosis among adults, this relationship remains uncertain in pediatric patients, prompting a new study.

Martin Runnström, MD, a fourth-year fellow at the Emory University School of Medicine, describes a study he presented at CHEST 2022 showing a reduced response to a 2-dose immunization series for SARS-CoV-2 among patients using biologics to treat severe asthma or atopic dermatitis.

Experts discuss the impact of supportive care in the MDS treatment landscape.

Drs Zeidan and Fazal share their opinions on setting appropriate goals for treatment of patients with MDS.

The report found people using continuous monitoring systems spent more time in their target glucose ranges.

As understanding of COVID-19 evolves and more evidence on treatments emerges, making sense of it can be a challenge for physicians.

Results will be presented at an upcoming medical conference.